169 related articles for article (PubMed ID: 2488327)
1. Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.
West WH
Immunol Ser; 1989; 48():79-92. PubMed ID: 2488327
[No Abstract] [Full Text] [Related]
2. Lymphokine-activated killer lymphocytes: extramural clinical trials.
Sniecinski IJ
Immunol Ser; 1989; 48():59-77. PubMed ID: 2488326
[No Abstract] [Full Text] [Related]
3. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.
Clark J; Longo DL
Immunol Ser; 1989; 48():37-58. PubMed ID: 2488325
[No Abstract] [Full Text] [Related]
4. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
Oldham RK
Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
[No Abstract] [Full Text] [Related]
5. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
Blacklock JB; Grimm EA
Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328
[No Abstract] [Full Text] [Related]
6. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M
Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596
[TBL] [Abstract][Full Text] [Related]
7. Clinical/technical challenges in adoptive cellular immunotherapy: in vitro culture techniques.
Yannelli JR; Jadus MR; Beckner S; Lacerna LV; Oldham RK
Immunol Ser; 1989; 48():191-206. PubMed ID: 2488322
[No Abstract] [Full Text] [Related]
8. [Immunotherapy of malignant melanoma].
Flageul B; Miclea JM; Bensussan A; Degos L
Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
[No Abstract] [Full Text] [Related]
9. Clinical use of interleukin-2 in treating cancer.
Patterson DL; Wiemann MC
Indiana Med; 1991 Aug; 84(8):534-7. PubMed ID: 1918915
[No Abstract] [Full Text] [Related]
10. [Our experience with lymphocytes activated against cancer: CTL cells].
Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes.
Wolf JA; Grimm EA
Curr Opin Oncol; 1989 Dec; 1(2):249-57. PubMed ID: 2489968
[No Abstract] [Full Text] [Related]
12. Adoptive cellular immunotherapy of cancer: future perspectives.
Stevenson HC
Immunol Ser; 1989; 48():229-36. PubMed ID: 2488324
[No Abstract] [Full Text] [Related]
13. [Adoptive immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes].
van de Loosdrecht AA; Ossenkoppele GJ; Beelen RH
Ned Tijdschr Geneeskd; 1989 Oct; 133(40):1994-5. PubMed ID: 2812087
[No Abstract] [Full Text] [Related]
14. Interleukin-2: basic biology and therapeutic use.
Williams TM; Fox KR; Kant JA
Hematol Pathol; 1991; 5(2):45-55. PubMed ID: 1894582
[No Abstract] [Full Text] [Related]
15. [Adoptive immunotherapy with interleukin-2 and with interleukin-2 activated lymphocytes].
Eggermont AM; Stoter G; Jansen RL; Bolhuis RL
Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1387-92. PubMed ID: 2677757
[No Abstract] [Full Text] [Related]
16. LAK cell therapy--clinical studies and future potential.
Marshall GD; Schwartzberg LS; Tauer KW; Lee P; Holbert JM; West WH
Prog Clin Biol Res; 1990; 337():555-8. PubMed ID: 2191342
[No Abstract] [Full Text] [Related]
17. Adoptive cellular therapy.
Urba WJ; Longo DL
Cancer Chemother Biol Response Modif; 1990; 11():265-80. PubMed ID: 2223395
[No Abstract] [Full Text] [Related]
18. Tumor-derived activated cells: culture conditions and characterization.
Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
[No Abstract] [Full Text] [Related]
19. New perspectives in immunotherapy of leukemia.
Lotzová E
Immunol Ser; 1994; 61():231-8. PubMed ID: 8011747
[No Abstract] [Full Text] [Related]
20. [Quality control of biological therapy in patients with tumors].
Zhang S
Zhonghua Yi Xue Za Zhi; 1996 Jul; 76(7):483-4. PubMed ID: 9275493
[No Abstract] [Full Text] [Related]
[Next] [New Search]
